|
We have continued to increase our access to novel therapeutic targets by establishing collaborations
with other companies and institutions that have identified potential therapeutic targets or have created
platforms for the identification of such targets. We actively seek opportunities to in-license and/or acquire
such targets and intend to develop novel therapeutic products by producing fully human antibodies that
interact with such targets.
Typically, a collaborator will provide one or more target antigen(s),
and we will generate and develop antibodies against the antigen(s) using
our UltiMAb technology. We and our collaborators typically agree to
share equally the costs of clinical development and manufacturing, as
well as revenues, expenses and profits associated with any products
arising under the collaboration. We believe this allows us to
participate in the research and development of substantially more
potential candidates than we could develop on our own if we bore the
entire cost of development.
| 
